SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001720725-19-000012
Filing Date
2019-12-03
Accepted
2019-12-03 07:24:41
Documents
58
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q oyst-20190930.htm   iXBRL 10-Q 1525943
2 EX-31 q3-19ex311.htm EX-31.1 14965
3 EX-31.2 q3-19ex312.htm EX-31.2 15316
4 EX-32.1 q3-19ex321.htm EX-32.1 10057
5 EX-32.2 q3-19ex322.htm EX-32.2 10052
  Complete submission text file 0001720725-19-000012.txt   5297904

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20190930.xsd EX-101.SCH 27890
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT oyst-20190930_cal.xml EX-101.CAL 51726
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT oyst-20190930_def.xml EX-101.DEF 192192
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20190930_lab.xml EX-101.LAB 368304
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20190930_pre.xml EX-101.PRE 277298
39 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20190930_htm.xml XML 809790
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39112 | Film No.: 191264629
SIC: 2836 Biological Products, (No Diagnostic Substances)